Table 7.

Adverse effects by type occurred in more than 5% of patients during psilocybin treatment.

Author, Year	Number of Assessed Patients	Dose	Psychiatric	Neurological	Cardiovascular	Gastroenterological	General
Griffiths, R. 2016 [41]	50 cross-over	(high dose 22 or 30 mg/70 kg), (low dose 1 or 3 mg/70 kg)	psychological discomfort: 32 (high dose), 12 (low dose); transient anxiety: 26 (high dose), 15 (low dose)	-	elevation in SBP: 34 (high dose), 17 (low dose); DBP: 12 (high dose), 2 (low dose)	nausea/vomiting: 15 (high dose session), 0 (low dose)	physical discomfort: 21 (high dose session), 8 (low dose session)
Ross, S. 2016 [42]	28 cross-over	0.3 mg/kg	transient anxiety: 17; transient psychotic-like symptoms: 7	headaches/migraine: 28	elevation in BP and HR: 76	nausea: 14	-
Carhart-Harris, R. 2021 [43]	30 (6-week trial period), 30 (dosing-day 1)	25 mg	feeling jittery: 7 (6-week trial), 0 (dosing-day 1)	headaches: 67 (6-week trial), 43 (dosing-day 1); migraine: 10 (6-week trial), 0 (dosing-day 1); dizziness: 7 (6-week trial)	-	nausea: 27 (6-week trial), 13 (dosing-day 1); vomiting: 7 (6-week trial), 0 (dosing-day 1	fatigue: 7 (6-week trial), 0 (dosing-day 1)